XML 41 R21.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Common Stock and Stock-Based Incentive Compensation Plans | 12 Months Ended
--- | ---
Dec. 28, 2024
Share-Based Payment Arrangement [Abstract] |
Common Stock and Stock-Based Incentive Compensation Plans | Common Stock and Stock-Based Compensation Common Stock Shares of common stock outstanding were as follows:
| Year Ended
| December 28, 2024 |  | December 30, 2023 |  | December 31, 2022
| (In millions)
Balance, beginning of period | 1,616 |  |  | 1,612 |  |  | 1,207 |
Common stock issued in the acquisition of Xilinx | — |  |  | — |  |  | 429 |
Common stock issued under employee equity plans | 17 |  |  | 17 |  |  | 17 |
Repurchases of common stock | (6) |  |  | (10) |  |  | (36) |
Common stock repurchases for tax withholding on equity awards | (5) |  |  | (4) |  |  | (5) |
Issuance of common stock upon warrant exercise | — |  |  | 1 |  |  | — |
Balance, end of period | 1,622 |  |  | 1,616 |  |  | 1,612 |
Stock Repurchase Program The Company has an approved stock repurchase program authorizing repurchases of up to $12 billion of the Company’s common stock (Repurchase Program). During the year ended December 28, 2024, the Company repurchased 5.9 million shares of its common stock under the Repurchase Program for $862 million. As of December 28, 2024, $4.7 billion remained available for future stock repurchases under this program. This Repurchase Program does not obligate the Company to acquire any common stock, has no termination date and may be suspended or discontinued at any time. Stock-Based Compensation The Company’s employee equity programs are intended to attract, retain and motivate highly qualified employees. On May 18, 2023, the Company’s stockholders approved the AMD 2023 Equity Incentive Plan (the 2023 Plan), which supersedes the AMD 2004 Equity Incentive Plan and the Xilinx, Inc. 2007 Equity Incentive Plan (the Prior Plans). Outstanding awards granted under the Prior Plans will continue to be governed by the terms of the Prior Plans but no awards may be made under the Prior Plans on or after May 18, 2023. Under the 2023 Plan, 87,645,874 shares of the Company’s common stock are reserved and available for delivery pursuant to awards granted under the 2023 Plan. Generally, stock options granted under the 2023 Plan vest and become exercisable over a four-year period from the date of grant and expire within seven years after the grant date. Unvested shares from the 2023 Plan that are reacquired by the Company from forfeited outstanding equity awards become available for grant and may be reissued as new awards. Under the 2023 Plan, the Company can grant (i) stock options, and (ii) RSUs, including time-based RSUs and PRSUs. Stock Options. Under the 2023 Plan, nonstatutory and incentive stock options may be granted. The exercise price of the shares subject to each nonstatutory stock option and incentive stock option cannot be less than 100% of the fair market value of the Company’s common stock on the date of the grant. The exercise price of each option granted under the 2023 Plan must be paid in full at the time of the exercise. Time-based RSUs. Time-based RSUs are awards that can be granted to any employee, director or consultant and that obligate the Company to issue a specific number of shares of the Company’s common stock in the future if the vesting terms and conditions are satisfied. PRSUs. PRSUs can be granted to certain of the Company’s senior executives. The performance metrics can be financial performance, non-financial performance and/or market conditions. Each PRSU award reflects a target number of shares (Target Shares) that may be issued to an award recipient before adjusting based on the Company’s financial performance, non-financial performance and/or market conditions. The actual number of shares that a grant recipient receives at the end of the period may range from 0% to 250% of the Target Shares granted, depending upon the degree of achievement of the performance target designated by each individual award. ESPP. Under the 2017 Plan, eligible employees who participate in an offering period may have up to 15% of their eligible earnings withheld, up to certain limitations, to purchase shares of common stock at 85% of the lower of the fair market value on the first or the last business day of the six-month offering period. The offering periods commence in May and November each year. As of December 28, 2024, the Company had 60 million shares of common stock that were available for future grants and 34 million shares reserved for issuance upon the exercise of outstanding stock options or the vesting of unvested RSUs, including PRSUs, under the 2023 Plan and the Prior Plans. Valuation and Expense Stock-based compensation expense was allocated in the Company’s Consolidated Statements of Operations as follows:
| Year Ended
| December 28, 2024 |  | December 30, 2023 |  | December 31, 2022
| (In millions)
Cost of sales | $ | 21 |  |  | $ | 30 |  |  | $ | 29 |
Research and development | 1,079 |  |  | 1,002 |  |  | 697 |
Marketing, general, and administrative | 307 |  |  | 352 |  |  | 355 |
Total stock-based compensation expense before income taxes | 1,407 |  |  | 1,384 |  |  | 1,081 |
Income tax benefit | (251) |  |  | (249) |  |  | (179) |
Total stock-based compensation expense, net of income taxes | $ | 1,156 |  |  | $ | 1,135 |  |  | $ | 902 |
Stock Options. The weighted-average estimated fair value of employee stock options granted during 2024, 2023 and 2022 was $68.38, $53.72 and $44.35 per share, respectively, using the following assumptions:
| December 28, 2024 |  | December 30, 2023 |  | December 31, 2022
Expected volatility | 54.34 | % |  | 52.36% - 52.42% |  | 51.28 | %
Risk-free interest rate | 3.80 | % |  | 3.93% - 4.11% |  | 3.00 | %
Expected dividends | — | % |  | — | % |  | — | %
Expected life (in years) | 4.98 |  | 4.96 - 5.04 |  | 4.75
The Company uses a combination of the historical volatility of its common stock and the implied volatility for publicly traded options on the Company’s common stock as the expected volatility assumption. The risk-free interest rate is based on the rate for a U.S. Treasury zero-coupon yield curve with a term that approximates the expected life of the option grant at the date closest to the option grant date. The expected dividend yield is zero as the Company does not expect to pay dividends in the near future. The expected term of employee stock options represents the weighted-average period the stock options are expected to remain outstanding. The following table summarizes stock option activity and related information:
| Outstanding Number of Shares |  | Weighted- Average Exercise Price |  | Aggregate Intrinsic Value |  | Weighted-Average Remaining Contractual Life (in years)
| (In millions, except share price) |  |
Balance as of December 30, 2023 | 3 |  |  | $ | 68.33 |  |  |  |  |
Granted | — |  |  | $ | 134.27 |  |  |  |  |
Forfeited | — |  |  | $ | 102.71 |  |  |  |  |
Exercised | (1) |  |  | $ | 22.17 |  |  |  |  |
Balance as of December 28, 2024 | 2 |  |  | $ | 89.73 |  |  | $ | 81 |  |  | 3.92
Exercisable December 28, 2024 | 1 |  |  | $ | 74.61 |  |  | $ | 69 |  |  | 2.83
The total intrinsic value of stock options exercised for 2024, 2023 and 2022 was $86 million, $173 million and $139 million, respectively. As of December 28, 2024, the Company had $41 million of total unrecognized compensation expense related to stock options, which will be recognized over the weighted-average period of 2.71 years. Time-based RSUs. The weighted-average grant date fair values of time-based RSUs granted during 2024, 2023 and 2022 were $141.95, $106.28 and $92.92 per share, respectively. The following table summarizes time-based RSU activity and related information:
| Number of Shares |  | Weighted- Average Grant Date Fair Value |  |  |  |
| (In millions) |  |  |  |  |  |
Unvested shares as of December 30, 2023 | 32 |  |  | $ | 100.65 |  |  |  |  |
Granted | 12 |  |  | $ | 141.95 |  |  |  |  |
Forfeited | (1) |  |  | $ | 107.96 |  |  |  |  |
Vested | (13) |  |  | $ | 101.35 |  |  |  |  |
Unvested shares as of December 28, 2024 | 30 |  |  | $ | 116.77 |  |  |  |  |
The total fair value of time-based RSUs vested during 2024, 2023 and 2022 was $2.0 billion, $1.1 billion and $889 million, respectively. As of December 28, 2024, the Company had $2.6 billion of total unrecognized compensation expense related to time-based RSUs, which will be recognized over the weighted-average period of 2.63 years. PRSUs. The weighted-average grant date fair values of PRSUs granted during 2024, 2023 and 2022 were $118.98, $134.87 and $121.12, respectively, using the following assumptions:
| December 28, 2024 |  | December 30, 2023 |  | December 31, 2022
Expected volatility | 52.68% - 53.19% |  | 51.12% - 56.22% |  | 50.65% - 53.51%
Risk-free interest rate | 3.82% - 4.41% |  | 4.30% - 4.36% |  | 1.14%- 3.17%
Expected dividends | — | % |  | — | % |  | — | %
Expected term (in years) | 2.48 - 3.00 |  | 2.17 - 3.00 |  | 2.07 - 3.07
The Company uses the historical volatility of its common stock and risk-free interest rate based on the rate for a U.S. Treasury zero-coupon yield curve with a term that approximates the expected life of the PRSUs grant at the date closest to the grant date. The expected dividend yield is zero as the Company does not expect to pay dividends in the near future. The expected term of PRSUs represents the requisite service periods of these PRSUs. The following table summarizes PRSU activity and related information:
| Number of Shares |  | Weighted-Average Grant Date Fair Value |  |  |  |
| (In millions) |  |  |  |  |  |
Unvested shares as of December 30, 2023 | 2 |  |  | $ | 117.65 |  |  |  |  |
Granted | 1 |  |  | $ | 118.98 |  |  |  |  |
Forfeited | — |  |  | $ | 132.80 |  |  |  |  |
Vested | (1) |  |  | $ | 91.15 |  |  |  |  |
Unvested shares as of December 28, 2024 | 2 |  |  | $ | 139.31 |  |  |  |  |
The total fair value of PRSUs vested during 2024, 2023 and 2022 was $226 million, $100 million and $254 million, respectively. As of December 28, 2024, the Company had $154 million of total unrecognized compensation expense related to PRSUs, which will be recognized over the weighted-average period of 1.61 years. ESPP. The weighted-average grant date fair value for the ESPP during 2024, 2023 and 2022 was $43.80, $31.11 and $24.71 per share, respectively, using the following assumptions:
| December 28, 2024 |  | December 30, 2023 |  | December 31, 2022 |  |  |  |
Expected volatility | 48.14% - 49.38% |  | 45.74% - 49.40% |  | 58.15% - 63.76% |  |  |  |
Risk-free interest rate | 4.42% - 5.41% |  | 5.13% - 5.46% |  | 1.43% - 4.52% |  |  |  |
Expected dividends | — | % |  | — | % |  | — | % |  |  |  |
Expected term (in years) | 0.50 |  | 0.50 |  | 0.50 |  |  |  |
The Company uses the historical volatility of its common stock and the risk-free interest rate based on the rate for a U.S. Treasury zero-coupon yield curve with a term that approximates the expected life of the ESPP grant at the date closest to the ESPP grant date. The expected dividend yield is zero as the Company does not expect to pay dividends in the near future. The expected term of the ESPP represents the six-month offering period. During 2024, 2 million shares of common stock were purchased under the ESPP at an average purchase price of $111 resulting in aggregate cash proceeds of $265 million. As of December 28, 2024, the Company had $43 million of total unrecognized compensation expense related to the ESPP, which will be recognized over the weighted-average period of 0.37 years.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration